Visual performance and patient-reported outcomes of a non-apodized diffractive trifocal intraocular lens in Chinese cataract patients: a prospective multicenter real-world study - Report - MDSpire
Advertisement
Visual performance and patient-reported outcomes of a non-apodized diffractive trifocal intraocular lens in Chinese cataract patients: a prospective multicenter real-world study
Clinical Report: Evaluation of Visual Outcomes with a Trifocal IOL in China
Overview
This study evaluates the visual performance and patient satisfaction following bilateral implantation of the AcrySof® IQ PanOptix® trifocal intraocular lens (IOL) in Chinese patients with cataracts.
Background
Cataracts are a leading cause of reversible visual impairment, particularly affecting older populations. Traditional cataract surgery often restores distance vision but does not address presbyopia, leading to continued reliance on spectacles. The development of trifocal IOLs, such as the PanOptix, aims to enhance functional vision at multiple distances.
Data Highlights
Outcome
Result
Mean binocular UDVA
0.017 ± 0.086 logMAR
Mean binocular UIVA
0.061 ± 0.110 logMAR
Mean binocular UNVA
0.061 ± 0.103 logMAR
Patients achieving ≤0.200 logMAR
91.24%
Refractive predictability within ±0.50 D
84.62%
Complete spectacle independence
96.90%
Key Findings
91.24% of patients achieved binocular visual acuity of ≤0.200 logMAR at all distances.
Mean binocular UDVA was 0.017 ± 0.086 logMAR at 3 months postoperatively.
High refractive predictability was observed, with 84.62% of eyes within ±0.50 D of emmetropia.
96.90% of patients reported complete independence from spectacles.
The binocular defocus curve maintained ≤0.200 logMAR between +0.50 D and −2.50 D.
Clinical Implications
No clinical implications are provided in the source material.
Conclusion
Bilateral implantation of the PanOptix trifocal IOL demonstrates visual performance and patient satisfaction in a clinical setting in China.
Forty-four years in, Heaton Eye is still learning, but its foundation hasn't changed. "We believe in the technologies we offer, we prepare our team for success, and we let the outcomes do the rest."
The key is execution, understanding the clinical landscape, controlling device cost, engineering the intraoperative workflow, and scheduling/staffing with intention.
